This study aimed to examine the impact of quetiapine on the symptom and distress domains measured by the Symptom Checklist-90-Revised (SCL-90-R) in patients with borderline personality disorder (BPD).
Methods
Ninety-five participants meeting DSM-IV diagnostic criteria for BPD were randomly assigned to low-dosage (quetiapine, 150 mg/d; n = 33), moderate-dosage (quetiapine, 300 mg/d; n = 33), or placebo (n = 29). SCL-90-R was administered weekly over the course of an 8-week double-blind treatment phase. We used a mixed-effects model to analyze subscale scores of the SCL-90-R.
Results
Results showed that both dosages of quetiapine were effective in reducing levels of overall psychological distress, interpersonal sensitivity, depression, and hostility compared with those who received placebo.
Conclusions
SCL-90-R can be a useful tool that would allow clinicians to collect information in addition to the DSM symptoms to better understand the diagnostic heterogeneity found in patients diagnosed with BPD.
Get full access to this article
View all access options for this article.
References
1.
GundersonJG, SingerMT.Defining borderline patients: an overview. Am J Psychiatry. 1975;132:1-10.
2.
GundersonJG, KolbJE, AustinVThe diagnostic interview for borderline patients. Am J Psychiatry. 1981;138:896–903.
3.
GoldbergSC, SchulzSC, SchulzPM, . Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680–686.
4.
SoloffPH, GeorgeA, NathanRS, . Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691–697.
5.
CowdryRW, GardnerDL.Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111–119.
6.
SoloffPH, CorneliusJ, GeorgeA, . Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377–385.
7.
Adityanjee, RomineA, BrownE, . Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008;20:219–226.
8.
SchulzSC, CamlinKL, BerrySA, . Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46:1429–1435.
9.
SzigethyEM, SchulzSC.Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psycho pharmacol. 1997;17:326–327.
10.
BogenschutzMP, George NurnbergH.Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–109.
11.
SchulzSC, ZanariniMC, BatemanA, . Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008; 193:485–492.
12.
ZanariniMC, SchulzSC, DetkeHC, . A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353-1362.
13.
ZanariniMC, VujanovicAA, ParachiniEA, . Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IVborderline psychopathology. J Pers Disord. 2003;17:233–242.
14.
SkodolAE, GundersonJG, PfohlB, . The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry. 2002;51:936-950.
SanislowCA, GriloCM, MoreyLC, . Confirmatory factor analysis of DSM-IV criteria for borderline personality disorder: findings from the collaborative longitudinal personality disorders study. Am J Psychiatry. 2002;159:284–290.
17.
LivesleyWJ.Suggestions for a framework for an empirically based classification of personality disorder. Can J Psychiatry. 1998;43:137–147.
18.
WidigerTA, SandersonCJ. Toward a dimensional model of personality disorders in DSM-IV and DSM-V In: LivesleyWJ, ed. The DSM-IV personality disorders. New York, NY: Guilford Press; 1995:433–458.
19.
BlackDW, ZanariniMC, RomineA, . Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171:1174–1182.
20.
DerogatisLR.SCL-90-R administration, scoring, and procedures manual II. Towson, MD: Clinical Psychometric Research;1983.
21.
ZanariniMC, GundersonJG, FrankenburgFR, . The Revised Diagnostic Interview for Borderlines: discriminating BPD from other Axis II disorders. J Pers Disord. 1989;3:10–18.
22.
Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association;2000.
23.
DerogatisLR.Symptom Checklist-90-Revised. In: American Psychiatric Association, ed. Handbook of psychiatric measures.Washington, DC: American Psychiatric Association;2000:81–84.
24.
MoriM, WoolsonRF, WoodworthGG.Slope estimation in the presence of informative right censoring: modeling the number of observations as a geometric random variable. Biometrics. 1994;50:39–50.
25.
MazumdarS, TangG, HouckPR, . Statistical analysis of longitudinal psychiatric data with dropouts. J Psychiatr Res. 2007;41:1032–1041.
26.
FitzmauriceGM, LairdNM, WareJH.Applied longitudinal analysis. New York, NY: Wiley & Sons;2004.
27.
SAS/STAT 9.1:User guide. Cary, NC: SAS Institute;2004.
28.
FrankenburgFR, ZanariniMC.Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442–446.
29.
IngenhovenT, LafayP, RinneT, . Effectiveness of pharmacotherapy for severe personality disorders: metaanalyses of randomized controlled trials. J Clin Psychiatry. 2010;71:14–25.
30.
KarterudS, FriisS, IrionT, . An SCL-90-derived Index of the severity of personality disorders. J Pers Disord. 1995;9:112–123.
31.
PerdersonG, KarterudS.Using measures from the SCL-90-R to screen for personality disorders. Personal Ment Health. 2010;4:121–132.
